Dx3 Injection 5mg/ml-1X5’s (Blister)

Description

Pregnancy

Risk cannot be ruled out. Lactation: Dx3 Injection 5mg/ml-1X5’s (Blister) Caution advised or effect undetermined. Contraindications: Hypercalcaemia, metastatic calcification, nephrolithiasis, hypercalciuria, nephrocalcinosis, hypervitaminosis D, severe arteriosclerosis, pseudohypoparathyroidism, severe renal impairment. Precautions: Check plasma calcium and phosphate regularly. Long term treatment; monitor serum and urinary calcium and renal function. Cardiovascular disorders. Osteoporosis due to immobilisation.Dx3 Injection 5mg/ml-1X5’s (Blister)

Indications

ORAL: Simple vitamin deficiency. Vit D deficiency due to Dx3 Injection 5mg/ml-1X5’s (Blister) intestinal malabsorption or chronic liver disease. Hypocalcaemia due to hypoparathyroidism or in patients with renal osteodystrophy. INJECTION; Rickets, osteomalacia, spasmophilia, paget’s disease, osteoporomalacia, fanconi Syndrome.

Dosage

INJECTION; Orally or as IM Injection: Adults: 10 mg twice a yr (5 mg/dose). See literature. Children: Neonates, 10 mg twice a yr (5 mg/dose). See literature. ORAL: Simple vit D deficiency: Adults & Children: 10 mcg (400 units) daily. Secondary vit D deficiency: Adults & Children: Up to 1 mg (40,000 units) daily in divided doses. Hypoparathyroidism: Adults & Children: Up to 2.5 mg (100,000 units) daily.

 Advice to Patient

Dx3 Injection 5mg/ml-1X5’s (Blister) Take with or without meals. Preferably taken after meals. Chew the chewable tablets or wafers thoroughly before swallowing. Do not swallow whole wafers. Contact prescriber immediately if there is nausea, vomiting; constipation, loss of appetite, increased thirst; increased urination, mental or mood changes, unusual tiredness, rash, itching or swelling of face, tongue or throat; severe dizziness or difficulty in breathing. If you are also taking other medications, take cholecalciferol at bedtime. Give a gap of 2 hours or more between doses of bile acid sequestrants such as cholestyramine or colestipol, mineral oil, orlistat.

Pharmacokinetics

Absorption: Readily absorbed from the small intestine. Metabolism: Hepatic, renal. Half-life elimination: Approx. 50 days. Time to peak, plasma: 7 days. Excretion: Bile. Faeces.

Interactions

Barbiturates, anticonvulsants, danazol, digitalis, thiazides, antacids, mineral oils, cholestyramine, colestipol, sucralfate, phenytoin, carbamazepine, glucocorticoids, digoxin, ion exchange resins, laxatives, orlistat, actinomycin, imidazole antifungals, rifampicin, isoniazid.

Adverse effects

Symptoms of overdose include anorexia, lassitude, nausea and vomiting, diarrhoea, constipation, weight loss, polyuria, sweating, headache, thirst, vertigo and raised concentration of calcium and phosphate in plasma and urine.